Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMNEON: Omarigliptin CV Outcomes Study
NCT01703208Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of omarigliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Oct 2012; status: terminated.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01703208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01703208.